Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.
Maria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolé et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III randomized controlled trial investigated the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) in 466 patients with high-risk early triple-negative breast cancer (TNBC) receiving adjuvant avelumab or observation. Higher baseline TILs (BSL-TILs) were associated with improved disease-free survival, particularly in patients with BSL-TILs ≥30%, showing a 3-year distant disease-free survival rate of 92% compared to 58.7%.
Key findings
- Higher BSL-TILs were independently associated with improved disease-free survival across all endpoints.
- In stratum B, higher RD-TILs significantly improved outcomes, outperforming BSL-TILs.
- Avelumab improved 3-year distant disease-free survival rates to 92% in patients with BSL-TILs ≥30%.
Why it matters
Understanding the role of TILs in predicting immunotherapy efficacy can help tailor treatment strategies for patients with high-risk early TNBC, potentially improving outcomes through personalized approaches.